WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million Added 151 new integrated projects, including 13 in late-stage and commercial stage Total integrated projects reached 817, one of the largest portfolios of complex biologics Research Services enabled 7 global programs for molecule discovery, eligible to receive ~$140 million in near-term payments Completed 16 ...